TrialAnnals of the rheumatic diseases2020

A randomised, double-blind, placebo-controlled, 24-week, phase II, proof-of-concept study of romilkimab (SAR156597) in early diffuse cutaneous systemic sclerosis.

Yannick Allanore et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.